BACKGROUND: End-stage renal disease is associated with reduced heart rate variability (HRV), components of which generally are associated with advanced age, diabetes mellitus and left ventricular hypertrophy. We hypothesized that daily in-center hemodialysis (HD) would increase HRV. METHODS: The Frequent Hemodialysis Network (FHN) Daily Trial randomized 245 patients to receive 12 months of six versus three times per week in-center HD. Two hundred and seven patients had baseline Holter recordings. HRV measures were calculated from 24-h Holter electrocardiograms at both baseline and 12 months in 131 patients and included low-frequency power (LF, a measure of sympathetic modulation), high-frequency power (HF, a measure of parasympathetic modulation) and standard deviation (SD) of the R-R interval (SDNN, a measure of beat-to-beat variation). RESULTS: Baseline to Month 12 change in LF was augmented by 50% [95% confidence interval (95% CI) 6.1-112%, P =0.022] and LF + HF was augmented by 40% (95% CI 3.3-88.4%, P = 0.03) in patients assigned to daily hemodialysis (DHD) compared with conventional HD. Changes in HF and SDNN were similar between the randomized groups. The effects of DHD on LF were attenuated by advanced age and diabetes mellitus (predefined subgroups). Changes in HF (r = -0.20, P = 0.02) and SDNN (r = -0.18, P = 0.04) were inversely associated with changes in left ventricular mass (LVM). CONCLUSIONS:DHD increased the LF component of HRV. Reduction of LVM by DHD was associated with increased vagal modulation of heart rate (HF) and with increased beat-to-beat heart rate variation (SDNN), suggesting an important functional correlate to the structural effects of DHD on the heart in uremia.
RCT Entities:
BACKGROUND: End-stage renal disease is associated with reduced heart rate variability (HRV), components of which generally are associated with advanced age, diabetes mellitus and left ventricular hypertrophy. We hypothesized that daily in-center hemodialysis (HD) would increase HRV. METHODS: The Frequent Hemodialysis Network (FHN) Daily Trial randomized 245 patients to receive 12 months of six versus three times per week in-center HD. Two hundred and seven patients had baseline Holter recordings. HRV measures were calculated from 24-h Holter electrocardiograms at both baseline and 12 months in 131 patients and included low-frequency power (LF, a measure of sympathetic modulation), high-frequency power (HF, a measure of parasympathetic modulation) and standard deviation (SD) of the R-R interval (SDNN, a measure of beat-to-beat variation). RESULTS: Baseline to Month 12 change in LF was augmented by 50% [95% confidence interval (95% CI) 6.1-112%, P =0.022] and LF + HF was augmented by 40% (95% CI 3.3-88.4%, P = 0.03) in patients assigned to daily hemodialysis (DHD) compared with conventional HD. Changes in HF and SDNN were similar between the randomized groups. The effects of DHD on LF were attenuated by advanced age and diabetes mellitus (predefined subgroups). Changes in HF (r = -0.20, P = 0.02) and SDNN (r = -0.18, P = 0.04) were inversely associated with changes in left ventricular mass (LVM). CONCLUSIONS:DHD increased the LF component of HRV. Reduction of LVM by DHD was associated with increased vagal modulation of heart rate (HF) and with increased beat-to-beat heart rate variation (SDNN), suggesting an important functional correlate to the structural effects of DHD on the heart in uremia.
Entities:
Keywords:
daily hemodialysis; end-stage renal disease; frequent hemodialysis network; heart rate variability; left ventricular mass
Authors: R S Suri; A X Garg; G M Chertow; N W Levin; M V Rocco; T Greene; G J Beck; J J Gassman; P W Eggers; R A Star; D B Ornt; A S Kliger Journal: Kidney Int Date: 2006-12-13 Impact factor: 10.612
Authors: Oliver Zilch; Pieter F Vos; P Liam Oey; Maarten-Jan M Cramer; Gerry Ligtenberg; Hein A Koomans; Peter J Blankestijn Journal: J Hypertens Date: 2007-06 Impact factor: 4.844
Authors: Jeffrey Perl; Laura M Dember; Joanne M Bargman; Teri Browne; David M Charytan; Jennifer E Flythe; LaTonya J Hickson; Adriana M Hung; Michel Jadoul; Timmy Chang Lee; Klemens B Meyer; Hamid Moradi; Tariq Shafi; Isaac Teitelbaum; Leslie P Wong; Christopher T Chan Journal: Clin J Am Soc Nephrol Date: 2017-03-17 Impact factor: 8.237
Authors: Sofia Skampardoni; Dimitrios Poulikakos; Marek Malik; Darren Green; Philip A Kalra Journal: Nephrol Dial Transplant Date: 2019-07-01 Impact factor: 5.992
Authors: Rachel M Kaplan; Charles A Herzog; Brett Larive; Haris Subacius; Bruce D Nearing; Richard Verrier; Rod S Passman Journal: Ann Noninvasive Electrocardiol Date: 2016-03-28 Impact factor: 1.468
Authors: Amith Roy Shamir; Ameet Karembelkar; Jonathan Yabes; Yi Yao; Dana Miskulin; Jennifer Gassman; David Ploth; Lavinia Negrea; Susan Paine; Mahboob Rahman; Raymond Y Kwong; Philip Zager; Manisha Jhamb Journal: Kidney Blood Press Res Date: 2018-05-30 Impact factor: 2.687
Authors: Jochen G Raimann; Christopher T Chan; John T Daugirdas; Thomas Depner; Tom Greene; George A Kaysen; Alan S Kliger; Peter Kotanko; Brett Larive; Gerald Beck; Robert McGregor Lindsay; Michael V Rocco; Glenn M Chertow; Nathan W Levin Journal: Kidney Blood Press Res Date: 2021-10-13 Impact factor: 3.096
Authors: Adam S Wilk; Richard A Hirth; Wei Zhang; John R C Wheeler; Marc N Turenne; Tammie A Nahra; Kathryn K Sleeman; Joseph M Messana Journal: Health Serv Res Date: 2017-01-19 Impact factor: 3.734